Activation of adenylate cyclase by forskolin increases the protein stability of RCAN1 (DSCR1 or Adapt78)  by Seo, Su Ryeon et al.
FEBS Letters 583 (2009) 3140–3144journal homepage: www.FEBSLetters .orgActivation of adenylate cyclase by forskolin increases the protein stability
of RCAN1 (DSCR1 or Adapt78)
Su Ryeon Seo a,*, Seon Sook Kim a, Kwang Chul Chung b,*
aDepartment of Molecular Bioscience, School of Bioscience and Biotechnology, Kangwon National University, Chuncheon 200-701, Republic of Korea
bDepartment of Biology, College of Life Science and Biotechnology, Yonsei University, Seoul 120-749, Republic of Koreaa r t i c l e i n f o
Article history:
Received 13 July 2009
Revised 8 September 2009
Accepted 9 September 2009
Available online 13 September 2009
Edited by Noboru Mizushima
Keywords:
Regulator of Calcineurin 1
Forskolin
Cyclic AMP
Calcineurin
NFAT0014-5793/$36.00  2009 Federation of European Bio
doi:10.1016/j.febslet.2009.09.019
Abbreviations: RCAN1, Regulator of Calcineurin 1;
phorbol myristate acetate
* Corresponding authors. Fax: +82 33 241 4627 (S.
Chung).
E-mail addresses: suryeonseo@kangwon.ac.kr (S.R
(K.C. Chung).a b s t r a c t
Overexpression of Regulator of Calcineurin 1 (RCAN1/DSCR1/Adapt78) is known to inhibit the calci-
neurin-NFAT dependent signaling pathway. In this report, we ﬁnd that activation of adenylate
cyclase by forskolin increases the expression of RCAN1 through the increase of the protein’s half-life.
The ability of forskolin to increase the accumulation of RCAN1 protein is signiﬁcantly inhibited with
protein kinase A inhibitors such as KT5720 and H-89. Furthermore, forskolin targets the central and
C-terminal region of RCAN1 and enhances the inhibitory effect of RCAN1 on the calcineurin-
mediated activation of NFAT. Our ﬁndings provide the ﬁrst evidence that the accumulation of the
RCAN1 protein by cAMP acts as an important regulatory mechanism in the control of the calcineu-
rin-dependent cellular pathway.
Structured summary:
MINT-7262390: PKA (uniprotkb:P22694) phosphorylates (MI:0217) RCAN1 (uniprotkb:P53805) by protein
kinase assay (MI:0424)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Regulator of Calcineurin 1 (RCAN1/DSCR1/Adapt78) was ﬁrst
identiﬁed as a Down Syndrome Critical Region 1 (DSCR1) gene
located in a region of human chromosome 21, of which trisomy
of the gene causes Down Syndrome (DS) [1–3]. The RCAN1 gene
consists of seven exons, and alternatively spliced [4]. The major
isoforms of RCAN1 protein are RCAN1-1, with the N-terminal ami-
no acids encoded by exon 1, and RCAN1-4, with the N-terminal
amino acids encoded by exon 4 [4]. The mRNA containing exon 1
encodes two potential translation initiation sites and might be
translated into two proteins such as RCAN1-1S (short) and
RCAN1-1L (long). All RCAN1 isoforms share 168 amino acids
encoded by exons 5, 6, and 7 [4]. RCAN1 gene is expressed in many
cell types and tissues such as brain, spinal cord, heart, liver and
skeletal muscle and is elevated in the brains of Alzheimer disease
patients (AD) [4,5]. Recent studies have indicated that RCAN1 playschemical Societies. Published by E
PKA, protein kinase A; PMA,
R. Seo), +82 2 312 5657 (K.C.
. Seo), kchung@yonsei.ac.kran important role in calcineurin signaling by acting as a negative
modulator through physical and functional association with calci-
neurin [5,6].
Calcineurin is a calcium/calmodulin-dependent serine/threo-
nine phosphatase that has been involved in many cellular signaling
processes such as synaptic plasticity and memory formation, T-cell
activation and apoptosis, muscle growth and differentiation, and
cardiac functions [7,8]. The most well characterized calcineurin
substrate is the nuclear factor of activated T cell (NFAT) family of
transcription factors [9]. Calcineurin activates the gene expression
of several targets by directly dephosphorylating NFAT in coopera-
tion with multiple partners including AP-1, MEF2, and GATA pro-
teins [7,10–12]. Dysregulation of calcineurin activity has also
been implicated with many forms of brain disease and injury,
including Alzheimer disease (AD) and ischemia [13,14].
Recently, RCAN1 expression has been shown to be dynamically
regulated by several intracellular signaling pathways [5,15–17].
Calcium and hydrogen peroxide regulates calcineurin-NFAT
signaling pathway by inducing the mRNA expression of RCAN1-
1S [5,15]. Glucocorticoids up-regulate the expression of RCAN1-1
in leukemic cells and Notch signaling down-regulates the
expression of RCAN1-1 and RCAN1-4 in keratinocyte growth and
differentiation [16,17]. After an ischemic insult, up-regulation of
RCAN1-4 in the per-infarct cortex has been reported [18]. Inlsevier B.V. All rights reserved.
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1L by phosphorylation can affect its protein stability via the ubiq-
uitin–proteasome pathway [19,20]. Based on the above reports, it
is likely that regulation of RCAN1 expression could potentially be
associated with a wide range of cellular and tissue functions.
In the present study, we examined the possible effects of intra-
cellular cAMP signaling pathway, which is important in neuronal
activity, on the regulation of RCAN1 expression. We found that
elevation of intracellular cAMP by forskolin increased the protein
stability of RCAN1 through the increase of the protein’s half-life.
Furthermore, increase of RCAN1 accumulation by forskolin
enhanced its inhibitory function on the calcineurin-mediated
activation of NFAT transcription. Our data reveal a new regulatory
mechanism of cAMP signaling on the negative regulation of calci-
neurin signaling pathway.HA-RCAN1-1S Blot: HA
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Fig. 1. Increased expression of RCAN1 by augmentation of intracellular cAMP
levels. SH-SY5Y cells were transfected with HA-RCAN1-1S for 24 h. (A) Cells were
treated with forskolin (10 lM) for the indicated times. (B) Cells were treated with
forskolin (10 lM) and 8CPT-cAMP (100 lM) for 2 h. (C) Cells were treated with
forskolin alone or together with IBMX (500 lM) for 2 h. The expression of HA-
RCAN1-1S was assessed by immunoblotting with an anti-HA antibody.2. Materials and methods
2.1. Materials and expression vectors
Anti-HA, anti-GAPDH, and anti-GFP antibodies were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phosphoser-
ine antibody, forskolin, CPT-cAMP, H-89, 3-isobutyl-1-methylxan-
thine (IBMX), ionomycin, catalytic subunit of protein kinase A
(PKA), and phorbol 12-myristate 13-acetate (PMA) were purchased
from Sigma–Aldrich (St. Louis, MO). The expression vector for tri-
ple HA-human RCAN1-1S (NM_203417) was kindly provided by
S. de la Luna. Expression vectors for wild-type and deletion con-
struct of GFP-RCAN1-4 were a gift from B.A. Rothermel. The
NFAT-driven reporter plasmid (pGL-IL2-luc) was kindly provided
by G.R. Crabtree. A polymerase chain reaction (PCR)-based proce-
dure was applied to generate point mutants in RCAN1 such as
S108A, 112A, and S108/112A.
2.2. Cell culture
Human neuronal SH-SY5Y cells were maintained in DMEM sup-
plemented with 10% FBS, penicillin, and streptomycin. Cells were
transfected with the expression vectors by the LipofectAmine
method (Invitrogen). After 24 h, cells were lysed in lysis buffer
[20 mM Tris–Cl (pH 7.9), 1% Nonidet P-40, 150 mM NaCl, 1 mM
EGTA, 10% glycerol, 1 mM Na3VO4, 1 lg/ml leupeptin, 1 lg/ml
aprotinin, 10 mMNaF, and 0.2 mM phenylmethylsulfonyl ﬂuoride].
2.3. Immunoprecipitation and immunoblotting
Cell lysates were subjected to immunoprecipitation with anti-
HA antibody for 2 h, followed by adsorption to Sepharose-coupled
protein G for 1 h. For immunoblot analysis, total cell lysates were
separated by 10% SDS–PAGE, and the proteins were transferred
to nitrocellulose membranes. The membranes were blocked in
TBST buffer [20 mM Tris–Cl (pH 7.6), 137 mM NaCl, 0.05%
Tween-20, and 3% non-fat dried milk] for 30 min and then incu-
bated overnight at 4 C in TBST buffer containing the appropriate
antibodies.
2.4. Pulse-chase analysis
For experiments examining the metabolic stability of RCAN1,
cells were preincubated for 1 h in Met/Cys-free DMEM and labeled
for 10 min with 100 lCi/ml [35S]-Met/Cys in Met/Cys-free DMEM.
The cells were chased for the indicated time periods and the cell
lysates were subjected to immunoprecipitation. The immunopre-
cipitates were resolved by SDS–PAGE, visualized with a phospho-
imager, and quantiﬁed.2.5. Reporter gene assays
SH-SY5Y cells were transfected with 0.5 lg of the each expres-
sion vectors by the LipofectAmine method (Invitrogen). Luciferase
activity was measured using the luciferase assay system (Promega)
and was normalized for transfection efﬁciency using a b-galactosi-
dase expressing vector (pCMV5.LacZ) and the Galacto-Star system
Perkin–Elmer).
2.6. RT-PCR
RNA preparation, reverse transcription, and PCR were per-
formed as described previously [21]. The primers were: RCAN1
forward, 50-GAGGAGGTGGACCTGCAGGACCTG-30; RCAN1 reverse,
50-TCAGCTGAGGTGGATCGGCGTGTAC-30; GAPDH forward, 50-ACC-
ACAGTCCATGCCATCAC-30; GAPDH reverse, 50-TCCACCACCCTGTT-
GCTGTA-30.
2.7. In vitro kinase assay
SH-SY5Y cells were transfected with the HA-RCAN1-1S and ex-
pressed for 24 h. Cell lysates were then subjected to immunopre-
cipitation with anti-IgG or anti-HA antibody for 2 h, followed by
adsorption to Sepharose-coupled protein G for 1 h. After washing
with lysis buffer, in vitro kinase assay was performed by incubat-
ing the immunoprecipitates with or without catalytic subunit of
PKA in the reaction buffer [20 mM HEPES (pH 7.4), 10 mM MgCl2,
2 mM DTT, 5 lCi [c-32P] ATP, and 100 lM ATP] at 30 C for
30 min. The reaction was stopped by adding SDS sample buffer
and subjected to SDS–PAGE. Phosphorylation was visualized by
autoradiography.
3. Results and discussion
3.1. Forskolin increases the steady-state amount of RCAN1
To investigate whether the cyclic adenosine monophosphate
(cAMP) signaling pathway could affect the steady-state level of
RCAN1 protein, we ectopically expressed HA-tagged RCAN1-1S in
neuronal SH-SY5Y cells and treated the cells with the adenylate
cyclase activator, forskolin (Fig. 1A). We observed that forskolin
increased the protein amount of RCAN1-1S in a time-dependent
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was caused by augmentation of intracellular cAMP levels since the
membrane permeable cAMP analogue 8CPT-cAMP, induced the
accumulation of RCAN1-1S to the same extent as forskolin
(Fig. 1B). Furthermore, treatment of 3-isobutyl-1-methylxanthine
(IBMX), a phosphodiesterase inhibitor, together with forskolin,
showed a signiﬁcant synergistic effect on the increase in RCAN1-
1S protein amount (Fig. 1C). Together, these results indicate that
an increase of intracellular cAMP by forskolin increases the amount
of RCAN1-1S.
3.2. Forskolin prolongs the half-life of RCAN1 protein
To test if signiﬁcant accumulation in RCAN1-1S protein by
forskolin was due to an increase in transcription, we performed
RT-PCR. As shown in Fig. 2A, the level of RCAN1-1 mRNA was not
signiﬁcantly altered by forskolin treatment, suggesting that for-
skolin did not affect the transcription of RCAN1-1S. We next exam-
ined whether increased amount of RCAN1 by forskolin was caused
by an increase in protein stability. To show that the accumulation
of RCAN1-1S by forskolin was due to an increase in the half-life of
the RCAN1 protein, we monitored the turnover rate of RCAN1-1S in
the presence or absence of forskolin by pulse-chase analysis. As
shown in Fig. 2B and C, treatment with forskolin signiﬁcantly
delayed the turnover rate of the newly synthesized RCAN1-1S
protein. Therefore, we conclude that forskolin induces an accumu-
lation of RCAN1-1S by increasing the protein’s half-life.
3.3. Forskolin increases the stability of RCAN1 protein through a PKA-
dependent mechanism
Next, we determined whether the cAMP-induced accumulation
of RCAN1-1S protein might occur through a PKA-dependent intra-B
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Fig. 2. Increased protein half-life of RCAN1-1S by forskolin. SH-SY5Y cells were
transfected with HA-RCAN1-1S for 24 h. (A) Cells were incubated in the presence or
absence of forskolin for 2 h followed by measuring mRNA levels of RCAN1-1S and
GAPDH by RT-PCR. (B) Transfected cells were pulse labeled with [35S]-Met/Cys and
chased for the indicated times in the presence or absence of forskolin. Cell lysates
were immunoprecipitated with an anti-HA antibody, and the [35S]-labeled HA-
RCAN1-1S proteins were visualized with a phosphoimager (B) and quantiﬁed (C).cellular signaling mechanism. As shown in Fig. 3A, preincubation of
cells with a well-known PKA speciﬁc inhibitor, KT5720 inhibited
the RCAN1-1S protein accumulation by either forskolin or 8CPT-
cAMP, suggesting that cAMP-PKA signaling pathway was involved
in the accumulation of RCAN1-1S protein.
We next explored whether forskolin increased the stability of
RCAN1-1S protein through phosphorylation of RCAN1-1S. As
shown in Fig. 3B, forskolin induced serine phosphorylation of
RCAN1-1S. Furthermore, inhibition of PKA with H-89 blocked the
serine phosphorylation of RCAN1-1S as well as the amount of
RCAN1-1S suggesting that stability of RCAN1-1S protein was regu-
lated by PKA (Fig. 3B). To conﬁrm the phosphorylation of RCAN1-
1S by PKA, we performed in vitro kinase assay. As shown in
Fig. 3C, the immunoprecipitated RCAN1-1S was phosphorylated
in the presence of catalytic subunit of PKA.
To further characterize whether the phosphorylation of RCAN1-
1S was required for the increased accumulation by forskolin, we
expressed the Ser mutants HA-RCAN1-1S (S108A) and S112A, as
well as double mutant S108/112A, which were previously known
to be phosphorylated by several kinases such as MEKK3, GSK3b,
and ERK [22,23]. As shown in Fig. 3D, forskolin increased the pro-
tein amounts of these mutants of RCAN1-1S to the same extent as
that of wild-type, indicating that these sites were not speciﬁcally
targeted by forskolin.B HA-RCAN1-1S
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Fig. 3. Forskolin increases the steady-state level of RCAN1-1S protein through PKA.
SH-SY5Y cells were transfected with the wild-type of HA-RCAN1-1S or with the
point mutants constructs of HA-RCAN1-1S for 24 h. (A) Cells were preincubated
with or without the indicated inhibitors KT5720 (3 lM) for 30 min followed by
treatment with forskolin or 8CPT-cAMP for 2 h. (B) Cells were preincubated with H-
89 (50 lM) for 30 min and the cell lysates were immunoprecipitated (IP) with an
anti-HA antibody and immunoblotted with an anti-phophoserine (p-Ser) antibody.
The expression of HA-RCAN1-1S was assessed by immunoblotting with anti-HA
antibody. (C) Cell lysates were immunoprecipitated (IP) with an anti-IgG or anti-HA
antibody. The immunoprecipitates were in vitro phosphorylated in the presence or
absence of catalytic PKA and visualized by autoradiography. (D) Cells were treated
with or without forskolin for 2 h and the expression of HA-RCAN1-1S were assessed
by immunoblotting with the HA-antibody.
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We next explored whether increased amount of RCAN1-1S pro-
tein by forskolin is an isoform-speciﬁc effect. For this, we ex-
pressed GFP tagged RCAN1-4 and treated the cells with forskolin
(Fig. 4A). As shown in Fig. 4A, we observed that forskolin increased
the protein amount of RCAN1-4. Furthermore, inhibition of PKA
with H-89 blocked the accumulation of RCAN1-4 suggesting that
the accumulation of RCAN1 protein by forskolin is not an iso-
form-speciﬁc effect.
To determine which regions of RCAN1-4 protein are speciﬁcally
targeted by forskolin for the increased protein accumulation, we
expressed several deletion constructs encoding the RCAN1-4 frag-
ments fused to GFP (Fig. 4B). We found that forskolin increased the
protein amount of the RCAN1-4 fragments containing amino acids
30–197 and 90–197, as well as the full length RCAN1-4. However,
forskolin had no effect on the expression of the RCAN1-4 fragments
containing the 90 N-terminal amino acids, suggesting that the
RCAN1-4 region critical for the increased protein stability by for-
skolin was within the amino acid residues 90–197. Since RCAN1-
4 fragments containing amino acids 90–197 is common in
RCAN1-1S and RCAN1-4 isoform (Fig. 4C), these results support
that the effect of forskolin to induce the accumulation of RCAN1
protein is not an isoform-speciﬁc and might be applied to both
isoforms.
3.5. Forskolin increases the inhibitory role of RCAN1 on NFAT
activation through its central and C-terminal region
Activation of calcineurin by calcium stimulators using a
combination of PMA and a Ca2+ ionophore dephosphorylates theA
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Fig. 4. Forskolin increases the protein amount of the central and C-terminal region
of RCAN1. (A and B) SH-SY5Y cells were transfected with the indicated constructs of
GFP-RCAN1-4 for 24 h. Cells were preincubated with or without H-89 for 30 min
followed by treatment with forskolin for 2 h. The expression of GFP-RCAN1-4 was
assessed by immunoblotting with the anti-GFP antibody. (C) Schematic diagram of
RCAN1 constructs.transcription factor, NFAT resulting in NFAT translocation to the
nucleus where it activates the transcription of target genes such
as IL2 [10,24]. Previous reports have suggested that RCAN1 can in-
hibit calcineurin-mediated NFAT-dependent gene transcription
[5,6]. To elucidate the functional role of forskolin in increasing
the stability of RCAN1 protein, we investigated whether forskolin
could affect the inhibitory activity of RCAN1 on calcineurin-medi-
ated NFAT luciferase activity of the IL2 promoter. As shown in
Fig. 5A, forskolin signiﬁcantly enhanced the inhibitory effect of
RCAN1-1S on calcineurin-mediated NFAT-transcriptional activity.
The inhibitory effect of the double serine mutant (Ser108/112A)
of RCAN1-1S on NFAT activation is the same extent as that of
wild-type, suggesting that these sites were not speciﬁcally targeted
for the enhanced inhibitory function of RCAN1-1S by forskolin
(Fig. 5A). Furthermore, Western blot of Fig 5A indicates that for-
skolin enhanced inhibitory activity of RCAN1-1S on NFAT-depen-
dent gene expression is due to an increase of the protein amount
of RCAN1-1S.
Consistent with this result, forskolin could not affect the ability
of the N-terminal fragment of RCAN1-4 (1–90) on NFAT-dependent
IL2 gene transcriptional activity (Fig. 5B), supporting that the
enhanced inhibitory function of RCAN1 on NFAT-dependent
transcription by forskolin was located in its central and C-terminal
region. Taken together, these results indicate that forskolin
enhances the inhibitory function of RCAN1 on calcineurin-induced
NFAT-transcriptional activation by increasing protein accumu
lation.
This study reports the ﬁrst evidence that activation of adenylate
cyclase by forskolin increases the expression of RCAN1 through
increasing the half-life of the protein. We suggest that the abilityLu
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Fig. 5. Forskolin enhances RCAN1-dependent inhibition of NFAT-transcriptional
activity. SH-SY5Y cells were transfected with 0.5 lg of IL2-luc reporter alone or in
the presence of the indicated RCAN1 constructs for 24 h. Cells were treated with
ionomycin (500 nM) plus PMA (10 ng/ml) for 6 h in the presence or absence of
forskolin. The results are normalized with b-galactosidase activity and are
represented as the means ± S.D. of three independent experiments.
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a PKA-dependent intracellular signaling mechanism. Several recent
report suggest the strong possibility that stability of short-lived
RCAN1 might be continuously regulated by the proteasome
through phosphorylation of RCAN1 [19,20,25]. For example, NF-
kB inducing kinase (NIK), which has been identiﬁed as a binding
partner of RCAN1 by yeast two hybrid screening, physically inter-
acts with RCAN1 and can phosphorylate it [20]. The phosphoryla-
tion thus leads to an increase in protein stability by attenuating
the proteasome-mediated degradation of RCAN1 [20]. In addition,
phosphorylation also increases the rate of RCAN1 degradation
[19]. In support of this, the SCFCDC4 E3 ubiquitin ligase complex
has recently been identiﬁed as an enzyme that triggers the degra-
dation of yeast Rcn1, a homologue of RCAN1 [26].
In the course of this study, we frequently detect exogenously
expressed HA-tagged RCAN1-1S protein as two different electro-
phoretic bands presumably by phosphorylation and non-phos-
phorylation. In support of this, mutated forms of RCAN1-1S in
which Ser 108 or Ser 112 are converted to Ala migrated faster by
Western blot analysis as compared with wild-type RCAN1-1S
(Fig. 3D). However, we have not been able to detect changes in
mobility with the expression of GFP tagged RCAN1-4 (Fig. 4A and
B). We speculate that the big size of GFP tag might function to in-
hibit the phosphorylation-dependent mobility shift of RCAN1-4
under our Western blot conditions.
Calcineurin is a Ca2+/calmodulin-dependent serine/threonine
phosphatase that coordinates a variety of cellular process [8,27].
Since RCAN1 was identiﬁed as a feedback inhibitor of the calcineu-
rin signaling pathway [6], we set out to investigate the functional
role of forskolin on the regulation of calcineurin activity by RCAN1.
Many reports have indicated that calcineurin activated NFAT
dephosphorylation is implicated in neuronal synaptic plasticity,
cardiac hypertrophy, T-cell activation, and vascular development
[28–31]. Our results show that the increased protein stability of
RCAN1 by forskolin enhances the negative regulatory effect of
RCAN1 on NFAT-dependent gene transcription. Thus it is likely that
activation of cAMP-PKA may enable RCAN1 to more effectively
oppose the calcineurin-mediated intracellular signaling pathway.
Based on our observations, it is tempting to speculate that by induc-
ing an accumulation of the RCAN1 protein, activation of cAMP-PKA
pathway could be used as a therapeutic strategy to attenuate calci-
neurin activity, an event that is activated in diverse pathologies
such as cerebral ischemia and neurodegenerative processes.
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